Related Experiment Video
Updated: Jul 6, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Acute treatment of cerebral venous and dural sinus thrombosis
José M Ferro1, Patrícia Canhão
1Department of Neurosciences, Serviço de Neurologia, Hospital de Santa Maria, University of Lisboa, Lisboa, Portugal. jmferro@fm.ul.pt.
Insights
Management of cerebral venous thrombosis (CVT) involves anticoagulation, which is safe even with intracranial hemorrhage. Treatment duration varies based on CVT cause and thrombophilia severity, ranging from 3 months to lifelong therapy.
Area of Science:
- Neurology
- Vascular Medicine
- Thrombosis Research
Background:
- Cerebral venous thrombosis (CVT) is a rare but serious condition.
- Effective management strategies are crucial for patient outcomes.
Purpose of the Study:
- To outline current management guidelines for CVT.
- To detail treatment approaches for acute and chronic phases of CVT.
Main Methods:
- Review of existing literature and clinical guidelines.
- Analysis of treatment options including anticoagulation, thrombolysis, and supportive care.
Main Results:
- Anticoagulation with heparin is recommended for acute CVT and is safe with intracranial hemorrhage.
- Treatment duration for anticoagulation varies from 3 months to lifelong, depending on risk factors and thrombophilia.
- Therapeutic lumbar puncture, hemicraniectomy, and antiepileptic drugs are used for specific complications.
Conclusions:
- CVT management requires a multi-faceted approach tailored to individual patient risk.
- Anticoagulation is the cornerstone of CVT treatment, with duration guided by clinical factors.
- Prompt recognition and management of complications are vital for improving prognosis.
Abstract:
Management of thrombosis of the dural sinus and cerebral veins (CVT) includes treatment of the underlying condition, antithrombotic treatment, symptomatic treatment, and the prevention or treatment of complications. Intravenous heparin or subcutaneous low-molecular-weight heparin should be used in acute CVT to prevent thrombus propagation and pulmonary embolism and to increase the chances of recanalization. Anticoagulation is safe and can be used in patients with acute CVT who have intracranial hemorrhagic lesions. Endovascular thrombolysis (with or without mechanical thrombus disruption) is an experimental treatment to be used in experienced centers for severe cases or patients who fail to improve on anticoagulation. Local thrombolysis is not useful in patients with large infarcts and impending herniation. In patients with severe headache and papilledema, intracranial hypertension can be reduced and symptoms relieved through a therapeutic lumbar puncture. Hemicraniectomy may be lifesaving in patients with parenchymal lesions leading to herniation. In patients with acute seizures and supratentorial lesions, antiepileptic drugs should be prescribed. Prophylactic use of these drugs can also be considered for patients with one of these risk factors but should be avoided in patients with neither of them. To reduce the risk of recurrent deep venous thrombosis of the limbs, vitamin K antagonists are given for a variable period depending on the patient's inherent risk of thrombosis, aiming at an International Normalized Ratio of 2 to 3.5. If CVT is related to a transient risk factor (eg, pregnancy, infection), we recommend anticoagulants for 3 months. In patients with idiopathic CVT or CVT associated with "mild" thrombophilia, the period of anticoagulation must be extended to 6 to 12 months. In patients with "severe" thrombophilia (eg, two or more prothrombotic abnormalities or antiphospholipid syndrome), anticoagulants should be given for life. Patients with persistent symptoms of increased intracranial hypertension, visual loss, or both can be treated with repeated lumbar punctures or a lumboperitoneal shunt. For the prevention of remote seizures, antiepileptic drugs are recommended for patients with seizures in the acute phase and for those who experience a seizure after the acute phase. These drugs can also be considered for patients without seizures who have supratentorial hemorrhagic lesions or motor deficits.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care